A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Recruiting now · Phase 3
Conditions studied: Metastatic HER2-positive Breast Cancer
In brief
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.
Key facts
- Study ID
- NCT06435429
- Run by
- Jazz Pharmaceuticals
- People needed
- 550
- Starts
- 2024-08-13
- Expected to finish
- 2030-10-18
- Last updated by the study team
- 2026-02-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic Scottsdale - PPDS — Phoenix, Arizona, United States (enrolling)
- University of Arizona Cancer Center — Tucson, Arizona, United States (enrolling)
- The Oncology Institute Of Hope And Innovation — Cerritos, California, United States (enrolling)
- Los Angeles Hematology Oncology Medical Group Glendale — Glendale, California, United States (enrolling)
- USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS — Los Angeles, California, United States (enrolling)
- UCSF at Mission Bay MB — San Francisco, California, United States (enrolling)
- University of Colorado-Cancer Center-PPDS — Aurora, Colorado, United States (enrolling)
- Rocky Mountain Cancer Centers — Denver, Colorado, United States (enrolling)
- Medstar Georgetown University Hospital — Washington D.C., District of Columbia, United States (enrolling)
- Washington Cancer Center — Washington D.C., District of Columbia, United States (enrolling)
- Florida Cancer Specialists Research South — Fort Myers, Florida, United States (enrolling)
- Mayo Clinic Jacksonville - PPDS — Jacksonville, Florida, United States (enrolling)
- Florida Cancer Specialists Research North — St. Petersburg, Florida, United States (enrolling)
- Florida Cancer Specialists Research East — West Palm Beach, Florida, United States (enrolling)
- Dana Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- Minnesota Oncology Hematology — Coon Rapids, Minnesota, United States (enrolling)
- Mayo Clinic - PPDS — Rochester, Minnesota, United States (enrolling)
- Saint Luke's Cancer Institute — Kansas City, Missouri, United States (enrolling)
- Hackensack Meridian Health — Hackensack, New Jersey, United States (enrolling)
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States (enrolling)
- Memorial Sloan Kettering — Long Island City, New York, United States (enrolling)
- Perlmutter Cancer Center 160 E 34th St — New York, New York, United States (enrolling)
- The Mount Sinai Hospital — New York, New York, United States (enrolling)
- Columbia University Medical Center 161 Fort Washington — New York, New York, United States (enrolling)
- Messino Cancer Center — Asheville, North Carolina, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.